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Abstract: Epmyema thoracis is associated with high mortality ranging between 6% to 24%. The incidence of empyema is increasing 
in both children and adults; the cause of this surge is unknown. Most cases of empyema complicate community- or hospital-acquired 
pneumonia but a proportion results from iatrogenic causes or develops without pneumonia. Parapneumonic effusions (PPE) develop 
in about one half of the patients hospitalized with pneumonia and their presence cause a four-fold increase in mortality. Three stages 
in the natural course of empyema have long been described: the exudative, fibrinopurulent, and organizing phases. Clinically, PPE are 
classified as simple PPE, complicated PPE, and frank empyema. Simple PPE are transudates with a pH . 7.20 whereas complicated 
PPE are exudates with glucose level ,2.2 mmol/l and pH , 7.20. Two guidelines statements on the management of PPE in adults have 
been published by the American College of Chest Physicians (ACCP) and the British Thoracic Society (BTS). Although they differ 
in their approach on how to manage PPE, they agree on drainage of the pleural space in complicated PPE and frank empyema. They 
also recommend the use of intrapleural fibrinolysis and surgical intervention in those who do not show improvement, but the level of 
  evidence for the use of intrapleural fibrinolysis is not high highlighting the need for more research in this area. A recently published large 
randomized trial has shown no survival advantage with the use of intrapleural streptokinase in patients with pleural infection. However, 
streptokinase enhances drainage of infected pleural fluid and may still be used in patients with large collection of infected pleural fluid 
causing breathlessness or ventilatory failure. There is emerging evidence that the combination of intrapleural tPA/DNase is significantly 
superior to tPA or DNase alone, or placebo in improving pleural fluid drainage in patients with pleural space infection. A guideline state-
ment on the management of PPE in children has been published by the BTS. It recommends the use of antibiotics in all patients with 
PPE in addition to either video-assisted thoracoscopic surgery (VATS) or tube thoracostomy and intrapleural fibrinolysis. Prospective 
randomized trials have shown that intrapleural fibrinolysis is as effective as VATS for the treatment of childhood empyema and is a more 
economic treatment and therefore, should be the primary treatment of choice.
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Introduction
Empyema thoracis, defined as collection of pus in 
the pleural space, has been recognized since the time 
of Hippocrates and historically has been associated 
with high mortality. The mortality rate from empy-
ema    thoracis  remains  high  and  it  ranges  between 
6%–24%.1–4  Pleural  infection  develops  in  65,000 
patients each year in the United States and the United 
Kingdom.5 A significant proportion of pleural space 
  infection   complicates community- or   hospital-acquired 
  pneumonia. However, a   proportion of pleural space 
infection  results  from  iatrogenic  causes;  it  is  also 
known  that  pleural  infection  may  develop  without 
pneumonia—so called primary empyema.
epidemiology of empyema
In recent years, there has been a surge in empyema 
incidence  in  both  children  and  adults  the  causes 
of  which  remain  speculative.6–14  The  incidence  of 
empyema in childhood is reported to be increasing 
in the UK and North America.6–9,11–13 In an analysis 
of 1349 admissions for empyema in childhood over 
an eight-year period in England, the highest increase 
in incidence was observed in the 1–4-year age group, 
with  a  rising  trend  in  admission  rates  seen  in  all 
children.7 Reasons for this increase in incidence are 
not  fully  understood,  but  may  include  an  increase 
in  pneumonia  incidence  among  the  paediatric 
population.  The  peak  incidence  of  pneumonia  in 
childhood is in those under 5 years of age,10 and a rise 
in pneumonia may plausibly account for the reported 
rise in empyema. However, a Scottish study reported 
longitudinal trends in incidence of childhood empy-
ema and pneumonia in Scotland over a 25-year period 
and has shown that empyema admissions increased 
after 1998 from 10 per million children per annum 
to reach a peak of 37 per million in 2005.11 In the 
1–4-year  age  group,  empyema  admissions  rose  in 
the late 1990s and 2000s from an average of 6.5 per 
million per year between 1981 and 1998 to 66 per 
million in 2005. Overall annual admission rates for 
pneumonia remained unchanged in most age groups 
and the authors conclude that the rise in empyema 
incidence is independent of pneumonia.11
In the Unite States, empyema associated hospi-
talizations rose by almost 70% during 2006 among 
  children  18  years  of  age  or  less  when    compared 
to  1997.12  This  was  independent  of  the  rate  of 
  hospitalization with bacterial pneumonia and invasive 
pneumococcal disease which have in fact decreased 
during the same period. Interestingly, pneumococcal 
conjugate vaccine did not decrease the incidence of 
empyema.12
Among adults, the incidence of empyema incre-
ased  significantly  by  1.2-fold  during  a  nine-year 
period between 1995 and 2003 in a North American 
study.13 Another study, from Utah in the United States, 
showed a more than six-fold increase in death rate 
from empyema during a 4-year period between 2000 
to 2004 when compared to death rate from empyema 
during 1950 to 1975.14
pathophysiology of parapneumonic 
effusions
PPE develop in up to 57% of patients hospitalized 
with bacterial pneumonias.5,15,16 The presence of PPE 
increases mortality in these patients by about   three- 
to six-fold.15,17 Almost 50 years ago, the   American 
Thoracic Society described three stages in the   natural 
course of empyema: the exudative, fibrinopurulent, 
and organizing phases.18 It is best to regard these stages 
as a continuum and that the development of   empyema 
in association with pneumonia is a   progressive process 
that starts as simple exudation and develops into the 
organizing phase. Exudative pleural fluid is derived 
from pulmonary interstitial fluid that is   associated with 
lung infection and inflammation; this fluid crosses the 
visceral pleura and accumulates in the pleural space 
and  is  usually  not  infected—  simple  PPE.  Simple 
PPE have characteristic biochemical and microbio-
logical features namely: pH . 7.2, LDH , 1000 iu/l, 
Glucose . 2.2 mmol/l and no   organisms in culture or 
gram stain. Treatment of simple PPE with antibiotics 
is likely to be adequate and there is no need for pleu-
ral fluid drainage.19 Some patients go on to develop 
complicated PPE. In these patients, bacterial invasion 
of simple PPE accelerates immune reaction leading 
to further migration of neutrophils and   activation of 
coagulation cascade.20,21 This favors fibrin deposition 
and  leads  to  septation  of  the  pleural  space.  The 
inflammatory process continues fueled by more bac-
terial death and phagocytes. This leads to the char-
acteristic biochemical and microbiological changes 
of complicated pleural effusions namely: pH , 7.20, Empyema thoracis
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glucose , 2.2 mmol/l, LDH . 1000 iu/l and possible 
positive gram stain and/or bacterial culture. This is 
followed by the organizing phase which may prog-
ress to formation of a solid pleural peel.
Bacteriology of empyema
In most series of patients with community acquired 
empyema,  aerobic  bacteria  predominate.22  These 
include  Streptococcus  pneumoniae  and  Staphylo-
coccus  aureus.22  Aerobic  organisms  also  include 
Gram    negative  bacteria  such  as  Escherichia  coli, 
Haemophilus influenza and Klebsiella pneumoniae.22 
Mixed aerobic and anaerobic bacteria are commonly 
isolated from empyema. The commonest anaerobes 
are  Bacteroides  fragilis23  In  the  United  Kingdom 
bacteria  commonly  isolated  from  hospital-acquired 
empyema  include  staphylococci,  enterobacteria, 
enterococci and Pseudomonus aeruginosa.24
Management of empyema in Adults
There  is  great  variation  in  the  management  of 
patients with PPE.2,26 The condition causes significant 
death,1–4,25  and  earlier  surveys  have  reported  even 
higher mortality rates27 and it may be that modern and 
timely therapeutic interventions have had an impact 
in  reducing  death  from  empyema.  Therefore,  the 
management of PPE is best based on guidelines.28–30 
These guidelines are evidence based and may also 
take into account expert opinion.28–30
Comparison of management  
guidelines in adults
Two  important  guidelines  for  the  management  of 
pleural space infection in adults have been published 
by the BTS and the ACCP.28,29 These two   documents 
adopted different approaches to the management of 
parapneumonic pleural effusions. The BTS   guidelines 
are  centered  around:  appropriate    antibiotics  use, 
  sampling and analysis of all parapneumonic   pleural 
effusions, early chest tube drainage for frank   empyema 
and complicated PPE, consideration of intrapleural 
fibrinolysis and prompt surgical referral if patients 
are not improving.28 A diagnostic algorithm for the 
management of patients with pleural infection may be 
found in the BTS guidelines.28
The ACCP guidelines, however, adopted a   different 
approach;  this  is  based  on  an  annotated  table  for 
  evaluating the risk for poor outcome in patients with 
PPE.29 Estimates of the risk of poor outcome were 
based  on  clinical  judgment  that,  without  adequate 
drainage of the pleural space, the patient with PPE 
would be likely to have any or all of: prolonged hos-
pitalization, prolonged evidence of systemic toxicity, 
increased  morbidity  from  any  drainage  procedure, 
increased risk for ventilatory impairment, increased 
risk for local spread of inflammatory reaction and 
increased mortality.29 Three variables, pleural space 
anatomy  (assessed  by  amount  of  pleural  fluid, 
  presence of loculated effusions or thickened parietal 
pleura), pleural fluid bacteriology (assessed by gram 
stain and or bacterial culture, or presence of pus), 
and pleural fluid chemistry (assessed by measuring 
pleural fluid pH) were used in the annotated table to 
categorize patients into four separate risk levels for 
poor outcome: very low risk, low risk, moderate risk 
and high risk.29 The ACCP statement supported drain-
age for patients with moderate or high risk for a poor 
outcome.29 Generally, these are patients who have a 
large amount PPE, loculated effusion or effusion with 
thickened parietal pleura; or have positive culture or 
gram stain; or pH , 7.20; or pus in pleural space.29 
Pleural fluid drainage may be done using therapeutic 
thoracocentesis or tube thoracostomy, but for most 
patients further treatment would be needed and fibrin-
olysis, VATS and surgery are acceptable approaches.
For  both  guidelines  documents  the  evidence 
for each intervention was graded as: A (controlled 
trials  with  consistent  results  or  individual  ran-
domized,  controlled  trials  with  narrow  confidence 
  intervals),  B  (controlled  cohort  and  case-control 
series),  C  (historically  controlled  series  and  case 
series), and D (expert opinion without explicit criti-
cal appraisal or based on physiology, bench research, 
or first   principles). It is worth noting that none of the 
intervention    recommendations  in  both  documents 
reached level A. In the BTS guidelines the highest 
level of recommendation reached was B in 36% of 
occasions and in 64% of occasions the level of evi-
dence was C.28 In the ACCP guidelines the highest 
level of recommendation reached was C in 60% of 
occasions and the rest was level D.29 This highlights 
the lack of good studies in many aspects regarding 
the  management  of  empyema  and  emphasizes  the 
need for more research in these areas.Ahmed and Yacoub
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Antibiotic therapy
Antibiotics  should  be  given  to  all  patients  with 
  pleural infection and if possible should be based on 
pleural fluid culture and sensitivities. Other factors 
that may affect the choice of antibiotics are the   ability 
of  an    antibiotic  to  penetrate  in  pleural  space  and 
the   presence of renal or hepatic impairment. In the 
absence of positive culture results,   antibiotics should 
be  chosen  to  cover  the  likely  organisms  that  may 
cause pleural space infection. For culture   negative 
pleural    infection,  a  regimen  proposed  by  the  BTS 
guideline document suggests intravenous cefuroxime 
1.5 grams 8 hourly plus metronidazole 500   milligrams 
8 hourly or   intravenous benzyl   penicillin 1.2 grams 
6 hourly plus ciprofloxacin 400 milligrams 12 hourly 
or    intravenous  meropenem  1  gram  8  hourly  plus 
metronidazole 500 milligrams 8 hourly for community 
acquired infection. For oral therapy the BTS guidelines 
document proposes amoxycillin 1 gram 8 hourly plus 
clavulanic acid 125 milligrams 8 hourly or amoxycil-
lin 1 gram 8 hourly plus metronidazole 400   milligrams 
8 hourly or clindamycin 300 milligrams 8 hourly.28
For culture negative hospital acquired infection, 
however, the the BTS guidelines document proposes 
intravenous piperacillin plus tozobactam 4.5 grams 
6 hourly or ceftazidime 2 grams 8 hourly or mero-
penem 1 gram 8 hourly to which metronidazole may 
be added at a dose 500 milligrams 8 hourly.28
The duration of treatment is variable and depends 
on patient’s response. Provided that there is adequate 
chest tube drainage long term treatment may not be 
necessary  and  treatment  for  about  three  weeks  is 
probably appropriate.28 Antibiotics may be changed 
to the oral route after sepsis has settled.28
Chest tube drainage
Traditionally  large  bore  chest  tubes  have  been 
  recommended  in  empyema  to  facilitate  drainage 
of  thick  pus.  However,  several  published  studies 
relate to the use of image guided small catheters and 
  suggest they have good primary outcome.31–33 Image 
guided small catheters have the advantage of draining 
  loculated pleural space and have shown success as 
rescue procedures as well.31–33 There are no controlled 
trials  comparing  large  bore  chest  tubes  to  smaller 
catheters.  Prompt  tube  drainage  is  recommended 
and is best done at the time of diagnostic sampling 
as delayed tube insertion has been associated with 
poorer outcome in retrospective human studies and a 
propective experimental animal model.4,26,34
Intrapleural fibrinolytic therapy
Intrapleural fibrinolytic therapy was first used more 
than 60 years ago.35 The aim of this therapy is to lyse 
the fibrinous septations within infected pleural space. 
Following the initial trial of intrapleural fibrinolytic 
therapy, there was a 32-year gap until the second study 
was published in 1981 mainly to address the effect of 
intrapleural streptokinase on systemic fibrinolysis;36 
it may be that concerns about side effects have led 
intrapleural streptokinase to fall out of use during that 
period.  Since  1981several    observational  series  and 
fewer controlled trials have been published.28,29,37,38 
The principal end points in these studies were amount 
of  fluid  drained,  either  as  absolute  volume  or  as 
  quantified by radiological improvement, and need for 
surgery. However, these studies have many limitations: 
first, many are observational uncontrolled trials the 
limitations of which are obvious;39 second, measuring 
the amount of pleural fluid drained may be deceptive 
as intrapleural streptokinase may induce pleural fluid 
accumulation;40 third, they did not have the statistical 
power to measure primary end points of clinical inter-
est such as patient mortality, need for surgery and 
residual lung volume.39 Clinical evidence of a benefit, 
therefore, remains marginal. Reviews performed by 
the Cochrane Collaboration describe existing data as 
incomplete and results should be treated with caution 
as the benefit of intrapleural fibrinolytic therapy is not 
significant in the subgroup of high quality studies.41
Recently,  a  large  United  Kingdom  multi-centre 
double-blind trial including 454 patients with   pleural 
infection  was  published.  Patients  were  randomly 
assigned  to  receive  either  streptokinase  (250,000 
units twice daily for three days) or placebo.42 The 
primary end points were death or need for surgical 
drainage at three months. The secondary end points 
were rates of death and surgery (analyzed separately), 
the    radiographic  outcome,  and  length  of  hospital 
stay.  There  was  no  significant  difference  between 
the groups who received streptokinase or placebo as 
  proportion of those or died or needed surgery:   relative 
risk,  1.14;  (95%  confidence  interval  0.85  to  1.54; 
P = 0.43).42 Regarding the secondary end points, there 
was no benefit to streptokinase in terms of mortality, 
rate of surgery, radiographic outcome, or length of Empyema thoracis
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  hospital stay.42 Serious adverse events including chest 
pain, fever, or allergy were more common in those 
who received streptokinase.42 These findings has led 
the authors conclude that fibrinolytic therapy should 
generally be avoided in pleural infection.42 However, 
it is important to remember that this study was not 
designed to readdress the effectiveness of streptoki-
nase in reducing the volume of infected pleural fluid 
collections as this has been established in previous 
studies.37,43 Therefore, there may still be a place for 
intrapleural fibrinolysis in treating some patients in 
whom large collection of infected pleural fluid causes 
shortness of breath or ventilatory failure.
Intrapleural DNase
Although streptokinase lyses adhesions, it does not 
reduce pus viscosity.44 It is possible that   combination 
of agents that reduce pus viscosity and break down 
loculations  may  be  more  effective  in  draining 
infected pleural space. Recently there has been an 
interest in intrapleural DNase as a possible candidate 
in   combination with thrombolytic therapy to enhance 
pus drainage.44 In an animal model, the combination of 
recombinant tissue plasminogen activator (alteplase) 
and  recombinant  human  deoxyribonnuclease  (rhD-
Nase) has been shown to be more effective in treating 
empyema than either agent used alone.45   Successful 
treatment  of  human  empyema  with  intrapleural 
  rhDNase given after intrapleural fibrinolytic therapy 
has been described in at least one case report.46
A multi-centre randomized trial of intrapleural   tissue 
plasminogen  activator  (tPA)  and  DNase  in    pleural 
infection has recently been completed but is currently 
only reported in abstract form.47 Two   hundred and ten 
patients with pleural space infection were   randomized 
to receive: double matched placebo, active tPA plus 
active  DNase,  active  tPA  plus  placebo  DNase,  or 
  placebo tPA plus active DNase for 3 days.   Combination 
intrapleural tPA/DNase was   significantly superior to the 
other combinations in improving   pleural fluid drainage. 
DNase alone appears to be associated with increased 
frequency of surgery/death. The proportion of patients 
dying or requiring surgery for their infection was higher 
in the DNase plus placebo group and similar in all other 
groups (number of deaths or surgery tPA/DNase 17.3%; 
placebo/placebo  12.7%;  tPA/placebo  15.4%;  DNase/
placebo 45.1%, X 2 3, P = 0.0001).47 A peer reviewed 
full report of this trial is eagerly awaited.
Surgical treatment
Many  surgical  techniques  have  been  employed  in 
the treatment of empyema including debridement via 
VATS, decortication, thoracoplasty and open window 
thoracostomy.48 Debridement via VATS has gained 
popularity from the mid 1990s,49 and its Success rate 
ranges from 68% to 93%.48 The success rate of VATS 
debridement very much depends on the stage of PPE 
and  the  more  patients  in  the  organizing  phase  the 
higher the failure rate.50
Decortication  is  the  method  of  choice  when 
the underlying lung is unable to expand due to the 
thick  inflammatory  coat  and  the  patient  is  fit  for 
major    surgery.51  Decortication  has  been  shown  to 
  substantially improve both vital capacity and forced 
expiratory volume in the first second.52   Thoracoplasty 
entails remodeling of the osteomuscular wall of the 
thoracic  cage  in  order  to  control  the  underlying 
inflammatory  process  but  is  rarely  done  these 
days.48 Another operative procedure—open window 
  thoracostomy—is  performed  in  debilitated  patients 
when thoracoplasty is not an alternative and when 
VATS has failed to control the disease. It can be done 
as a definite procedure with intent to cure, as a last 
resort procedure when other treatment has failed to 
achieve a relatively stable state or as a preliminary 
procedure prior to definite treatment.48,53
Management of empyema in children
The principal difference between adult and   paediatric 
empyema is that, since it is rare for children to have 
an  underlying  lung  disease,  the  prognosis  with 
  treatment  is  almost  always  excellent.30  The  BTS 
published an important separate guidelines docu-
ment for the management of pleural space infec-
tion in children.30 In this document the management 
of empyema is planned according to an algorithm. 
The algorithm recommends that all children with 
a  clinically    suspected  parapneumonic  effusion  or 
diagnosed pneumonia with treatment failure over 
48 hours should have chest radiographs and if these 
radiographs show   features of pleural effusion this 
should be confirmed by chest ultrasonography. Intra-
venous antibiotics should be given to all patients. 
In addition patients should receive either medical 
treatment in the form of chest tube drainage with 
pleural fluid sampling for microbiology at the same 
time of chest tube insertion or early surgery in the Ahmed and Yacoub
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form of VATS or mini-  thoracostomy. For those who 
were treated medically, if they were noted to have 
loculated pleural space or thick pus they should be 
candidates for intrapleural fibrinolysis. If patients 
do not improve after intrapleural fibrinolysis they 
should be referred for late surgery. For those who 
improve after chest tube drainage or surgery intra-
venous antibiotics may be changed to the oral route 
and continued for one to four weeks.30
The BTS guidelines document for the managent of 
pleural space infection in children grades the level of 
evidence for each intervention. A remarkable finding 
is that, like the adult guidelines documents, the level 
of evidence for interventions is low. It is worth noting 
that none of the intervention recommendations in the 
BTS  guidelines  document  for  the  management  of 
pleural space infection in children reached level A. 
The highest level of recommendation reached was 
B in 7% of occasions and in 12% of occasions the 
level of evidence was C and the rest was level D.30 
This emphasizes the need for more research in these 
areas.
Two  prospective  randomized  trials  compared 
thoracoscopic  decortication  to  tube  thoracostomy 
with fibrinolysis for empyema in children.54,55 Their 
findings  were  similar.  Sonnappa  et  al  randomized 
60  children  with  empyema  to  receive  either 
  percutanous chest drain with intrapleural urokinase 
or primary VATS.54 No significant difference between 
the two groups was found in length of hospital stay 
after intervention, total hospital stay or radiological 
  outcome at six months after intervention. However, 
the treatment costs for patients in the urokinase arm 
were  significantly  lower  than  those  for  the  VATS 
arm.54 St. Peter et al studied a total of 36 patients 
who were randomized to receive either three doses 
of 4 milligrams each of tissue   plasminogen activator 
via a 12F chest tube or   decortication via VATS.55 
There was no difference of days of hospitalization 
after  intervensions,  days  of  oxygen  requirement, 
days until afebrile, or analgesic requirements. VATS 
was  associated  with  significantly  higher  charges. 
Three patients in the fibrinolysis group subsequently 
required VATS and two in the VATS group required 
ventilator support one of whom required  temporary 
dialysis.55 It can be concluded from these two   studies 
that there is no difference in clinical outcome between 
intrapleural fibrinolysis and VATS for the treatment 
of  childhood  empyema.  Intrapleural  fibrinolyis  is 
a more economic treatment option compared with-
VATS and should be the   primary treatment of choice 
in children.
conclusion
Empyema  thoracis  is  a  cause  of  high    mortality 
in  man  and  its  occurrence  is  increasing  in  both 
  children and adults. Two guidelines documents on 
the   management of empyema in adults have been 
  published  by  the  ACCP  and  the  BTS.  Although 
they differ in their approach to management, they 
agree on that the   pleural space should be drained in 
all  patients  with  exudative  PPE  with  pleural  fluid 
pH , 7.2 and in those who have frank pus in the 
  pleural space. Patients who do not improve should 
be referred to the surgeon for further management. 
A large randomized multi-centre trial has shown no 
survival advantage with the use of   intrapleural strep-
tokinase in patients with pleural infection and the 
use of streptokinase has not prevented surgery in the 
group  of  patients  studied.  However,  streptokinase 
enhances  infected    pleural  fluid  drainage  and  may 
still be used in patients who have large collection of 
infected   pleural collection causing ventilatory impair-
ment. There is emerging evidence that combination 
of intrapleural tPA/DNase is significantly superior to 
tPA or DNase alone, or   placebo in improving pleural 
fluid drainage in patients with pleural space infec-
tion. A guideline document on the management of 
PPE in children has been published by the BTS. It 
recommends the use of antibiotics in all patients with 
PPE in   addition patients should be treated by either 
VATS or tube thoracostomy. For those who received 
tube   thoracostomy if there is thick pus or loculation 
of pleural space the guideline document recommends 
the use of intrapleural fibrinolysis.   Prospective ran-
domized trials have shown that there is no difference 
in clinical outcome between intrapleural fibrinolysis 
and VATS for the treatment of childhood empyema. 
Intrapleural fibrinolyis is a more economic treatment 
option compared withVATS and should be the pri-
mary treatment of choice in children.
Disclosures
This  manuscript  has  been  read  and  approved  by 
all authors. This paper is unique and is not under 
  consideration by any other publication and has not Empyema thoracis
  7 Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 2010:4  7
been  published  elsewhere.  The  authors  and  peer 
reviewers of this paper report no conflicts of interest. 
The  authors  confirm  that  they  have  permission  to 
reproduce any copyrighted material.
References
  1.  Davies CW, Kearney SE, Gleeson FV, Davies RJ. Predictors of outcome and 
longterm survival in patients with pleural infection. Am J Respir Crit Care 
Med. 1999;160:1682–7.
  2.  Ferguson AD, Prescott RJ, Selkon JB, Watson D, Swinburn CR. Empyema 
subcommittee of the Research Committee of the British Thoracic Society. 
The  clinical  course  and  management  of  thoracic  empyema.  Q  J  Med. 
1996;89:285–9.
  3.  Mandal AK, Thadepalli H, Mandal AK, Chettipally U. Outcome of primary 
empyema thoracic: therapeutic and microbiological aspects. Ann Thorac 
Surg. 1998;66:1782–6.
  4.  Ashbaugh  DG.  Empyema  thoracis.  Factors  influencing  morbidity  and 
mortality. Chest. 1991;99:1162–5.
  5.  Light  RW,  Girard  WM,  Jenkinson  SG,  George  RB.  Parapneumonic 
effusions. Am J Med. 1980;69:507–12.
  6.  Rees  JHM,  Spencer  DA,  Parikh  D,  Weller  P.  Increase  in  incidence  of 
childhood  empyema  in West  Midlands,  UK  [Research  Letters].  Lancet. 
1997;349:402.
  7.  Gupta R, Crowley S. Increasing paediatric empyema admissions [Letters]. 
Thorax. 2006;61:179–81.
  8.  Byington  CL,  Spencer  LY,  Johnson  TA,  et  al.  An  epidemiological 
investigation of a sustained high rate of pediatric parapneumonic empyema: 
risk factors and microbiological associations. Clin Infect Dis. 2002;34: 
434–40.
  9.  Schultz KD, Fan LL, Pinsky J, et al. The changing face of empyemas in 
children: epidemiology and management. Paediatrics. 2004;113:1735–40.
  10.  Farha  T,  Thomson  AH.  The  burden  of  pneumonia  in  children  in  the 
developed world. Paediatr Respir Rev. 2005;6:76–82.
  11.  Roxburgh  CSD,  Youngson  GG,  Townend  JA,  Turner  SW.  Trends  in 
pneumonia and empyema in Scottish children in the past 25 years. Arch Dis 
Child. 2008;93;316–8.
  12.  Li ST, Tancredi DJ. Empyema Hospitalizations Increased in US Children 
Despite Pneumococcal Conjugate Vaccine. Pediatrics. 2010;125(1):26–33.
  13.  Finley C, Clifton J, FitzGerald JM, Yee J. Empyema: an increasing concern 
in Canada. Can Respir J. 2008;15(2):85–9.
  14.  Bender  JM,  Ampofo  K,  Sheng  X,  Pavia  AT,  Cannon-Albright  L, 
Byington C. Parapneumonic Empyema Death during Past Centaury, Utah. 
Emerging Infectious Diseases. 2009;15(1):44–8.
  15.  Lim WS, Lewis S, Macfarlane JT. Severity prediction rules in community 
acquired pneumonia: a validation study. Thorax. 2000;55;219–23.
  16.  Taryle DA, Potts DE, Sahn SA. The incidence and clinical correlates of 
parapneumonic  effusions  in  pneumococcal  pneumonia.  Chest.  1978;74: 
170–3.
  17.  Hasley PB, Albaum MN, Li YH, et al. Do pulmonary radiographic findings 
at  presentation  predict  mortality  in  patients  with  community-acquired 
pneumonia? Arch Intern Med. 1996;156:2206–12.
  18.  Andrews NC, Parker EF, Shaw RP, et al. Management of non-tuberculous 
empyema. Am Rev Respir Dis. 1962;85:935–6.
  19.  Heffner JE, Brown LK, Barbieri C, Barbieri C, Deleo JM. Pleural fluid 
chemical  analysis  in  parapneumonic  effusions.  A  meta-analysis.  Am  J 
Respir Crit Care Med. 1995;151:1700–8.
  20.  Kroegel C, Anthony VB. Immunobiology of pleural inflammation: potential 
implications for pathogenesis, diagnosis and therapy. Eur Respir J. 1997; 
10:2411–8.
  21.  Idell  S,  Girard  W,  Koenig  KB,  McLarty  J,  Fair  DS. Abnormalities  of 
pathways of fibrin turnover in the human pleural space. Am Rev Respir Dis. 
1991;144:187–94.
  22.  Brook I, Frazier EH. Aerobic and anaerobic microbiology of empyema. A 
retrospective review in two military hospitals. Chest. 1993;103:1502–7.
  23.  Civen R, Jousimies-Somer H, Marina M, Borenstein L, Shah H, Finegold SM. 
A retrospective review of cases of anaerobic empyema and update of bacte-
riology. Clin Infect Dis. 1995;20(2):S224–9.
  24.  Chapman  SJ,  Davies  RJ.  The  management  of  pleural  space  infections. 
Respirology. 2004;9:4–11.
  25.  Tsang  KY,  Leung  WS,  Chan  VL,  Lin  AWL,  Chu  CM.  Complicated 
parapneumonic effusion and empyema thoracis: microbiology and predictors 
of adverse outcomes. Hong Kong Med J. 2007;13:178–86.
 26.  Heffner JE, McDonald J, Barbieri C, Klein J. Management of parapneumonic effu-
sions. An analysis of physician practice patterns. Arch Surg. 1995;130:433–8.
  27.  Graham EA. Some fundamental considerations in the treatment of empy-
ema thoracis. St. Louis: CV Mosby, 1925;7–110.
  28.  Davies CWH, Gleeson FV, Davies RJO. BTS guidelines for the manage-
ment of pleural infection. Thorax. 2003;58:ii18–28.
  29.  Colice GL, Curtis A, Deslauriers J, et al. Medical and surgical treatment 
of parapneumonis effusions: Evidence-Based Guideline. Chest. 2000;118; 
1158–71. [Erratum, Chest 2001;119:319.]
  30. Balfour-Lynn IM, Abrahamson E, Cohen G, et al. And on behalf of the Pae-
diatric Pleural Diseases Subcommittee of the BTS Standards of Care Com-
mittee.  BTS guidelines for the management of pleural infection in children. 
Thorax. 2005;60:i1–i21. 
  31.  Silverman SG, Mueller PR, Saini S, et al. Thoracic empyema: management 
with image-guided catheter drainage. Radiology. 1988;169:5–9.
  32.  Crouch JD, Keagy BA, Delany DJ. “Pigtail” catheter drainage in thoracic 
surgery. Am Rev Respir Dis. 1987;136:174–5.
  33.  Ulmer JL, Choplin RH, Reed JC. Image-guided catheter drainage of the 
infected pleural space. J Thorac Imaging. 1991;6:65–73.
  34.  Sasse S, Nguyen TK, Mulligan M, Wang N, Mahutte CK, Light RW. The 
Effects of Early Chest Tube Placement on Empyema Resolution. Chest. 
1997;111;1679–83.
  35.  Tillett WS, Sherry S. The effect in patients of streptococcal fibrinolysin 
(streptokinase) and streptococcal desoxyribonuclease on fibrinous, purulent, 
and sanguinous pleural exudations. J Clin Invest. 1949;28:173–90.
  36.  Berglin E, Ekroth R, Teger-Nilsson AC, William-Olsson G. Intrapleural 
instillation  of  streptokinase.  Effects  on  systemic  fibrinolysis.  Thorac 
Cardiovasc Surg. 1981;29:124–6.
  37.  Maskell NA, Davies RJO. Effusions from parapneumonic infection and 
empyema.  In:  Light  RW,  Lee YCG,  eds.  Textbook  of  pleural  diseases. 
London: Arnold. 2003:310–28.
  38.  Diacon AH, Theron J, Schuurmans MM, Van de Wal BW, Bolliger CT. 
Intrapleural streptokinase for empyema and complicated parapneumonic 
effusions. Am J Respir Crit Care Med. 2004;170:49–53.
  39.  Lee YCG. Ongoing search for effective intrapleural therapy for empyema: 
is streptokinase the answer? Am J Respir Crit Care Med. 2004;170:1–2.
  40.  Strange C, Allen ML, Harley R, Lazarchick J, Sahn SA. Intrapleural strepto-
kinase in experimental empyema. Am Rev Respir Dis. 1993;147:962–66.
  41.  Cameron RJ, Davies HRHR. Intra-pleural fibrinolytic therapy versus conser-
vative management in the treatment of adult parapneumonic effusions and 
empyema. Cochrane Database Systematic Reviews. 2008;2:CD002312.
  42.  Maskell NA, Davies CWH, Nunn AJ, et al. U.K. controlled trial of intrapleural 
streptokinase for pleural infection. N Engl J Med. 2005;352:865–74.
  43.  Davies  RJO,  Traill  ZC,  Gleeson  FV.  Randomised  controlled  trial  of 
intrapleural streptokinase in community acquired pleural infection. Thorax. 
1997;52:416–21.
 44.  Simpson G, Roomes D, Heron M. Effects of streptokinase and deoxyribonuclease 
on viscosity of human surgical and empyema pus. Chest. 2000; 117:1728–33.
  45.  Hawthorne ZZML, Guo Y, Drake W, Bilaceroglu S, Misra HL, Light RW. 
Tissue Plasminogen Activator Combined With Human Recombinant Deoxy-
ribonuclease Is Effective Therapy for Empyema in a Rabbit Model. Chest. 
2006;129;1577–83.
  46.  Simpson G, Roomes D, Reeves B. Successful treatment of empyema thoracis 
with human recombinant deoxyribonuclease. Thorax. 2003;58:365–6.
  47.  Rahman MM, Maskell N, Davies CWH, et al. Primary result of the second 
multicentre intrapleural sepsis (MIST2) trial; randomized trial of intrapleural 
tPA and DNase in pleural infection. Thorax. 2009;64 Suppl IV:A1.
  48.  Molnar TF. Current surgical treatment of thoracic empyema in adults. Eur J 
Cardiothorac Surg. 2007;32:422–30.publish with Libertas Academica and 
every scientist working in your field can 
read your article 
“I would like to say that this is the most author-friendly 
editing process I have experienced in over 150 
publications. Thank you most sincerely.”
“The communication between your staff and me has 
been terrific.  Whenever progress is made with the 
manuscript, I receive notice.  Quite honestly, I’ve 
never had such complete communication with a 
journal.”
“LA is different, and hopefully represents a kind of 
scientific publication machinery that removes the 
hurdles from free flow of scientific thought.”
Your paper will be:
•  Available to your entire community 
free of charge
•  Fairly and quickly peer reviewed
•  Yours!  You retain copyright
http://www.la-press.com
Ahmed and Yacoub
8  Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 2010:4 
  49.  Lawrence  DR,  Ohri  KS,  Moxon  RE,  Townsend  ER,  Fountain  SW. 
Thoracosocopic debridement of empyema thoracis. Ann Thorac Surg. 1997; 
64:1448–50.
  50.  Luh SP, Chou MC, Wang LS, Chen JY, Tsai TP. Video-assisted thoracoscopic 
surgery  in  the  treatment  of  complicated  parapneumonic  effusions  or 
empyemas. Chest. 2005;127:1427–32.
  51.  Anstadt MP, Guill CK, Ferguson ER, et al. Surgical versus nonsurgical 
treatment of empyema thoracis: an outcomes analysis. Am J Med Sci. 2003; 
326(1):9–14.
  52.  Rzyman W, Skokowski J, Romanowicz G, Lass P, Dziadziuszko R. Decortication 
in chronic pleural empyema—effect on lung function. Eur J Cardiothorac Surg. 
2002;21(3):502–7.
  53.  Regnard  JF, Alifano  M,  Puyo  P,  Fares  E,  Magdeleinat  P,  Levasseur  P. 
Open window thoracostomy followed by intrathoracic flap transposition 
in the treatment of empyema complicating pulmonary resection. J Thorac 
Cardiovasc Surg. 2000;120:270–5.
  54.  Sonnappa S, Cohen G, Owens CM, et al. Comparison of Urokinase and 
Video-assisted  Thoracoscopic  Surgery  for  Treatment  of  Childhood 
Empyema. Am J respire crit care med. 2006;174:221–7.
  55.  St. Peter SD. Tsao K. Harrison C, et al. Thoracoscopic decortication vs. 
tube thoracostomy with fibrinolysis for empyema in children: a prospective, 
randomized trial. J Pediatr Surg. 2009;44:106–11.